Biotricity Inc. (OTCQB: BTCY) provided guidance on February 17, 2025, for its financial results for the third quarter of fiscal year 2025, ended December 31, 2024. The company announced achieving cash flow breakeven for the quarter.
The guidance also indicated an 11% year-over-year and quarter-over-quarter revenue increase. These results highlight continued improvements in key operating metrics and a strong focus on cost control.
Management emphasized that these financial achievements demonstrate consistent progress towards the company's goal of achieving full profitability. The company continues to leverage its Biocore suite of products and AI-driven solutions to redefine medical diagnostics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.